Piramal Alzheimer's imaging agent gets EU thumbs up
This article was originally published in Scrip
The EU's CHMP has granted a positive opinion to marketing for another imaging agent for use in Alzheimer's disease, Piramal Imaging's NeuraCeq (florbetaben). It gave the go-ahead for Lilly and Avid Radiopharmaceuticals' Amyvid (florbetapir F 18 injection), the first Alzheimer's imaging agent to reach the market, in October 2012 (scripintelligence.com, 24 October 2012). GE Healthcare's similar product Vizamyl (18F flutemetamol) recently received US approval (scripintelligence.com, 30 October 2013).